인문학
사회과학
자연과학
공학
의약학
농수해양학
예술체육학
복합학
개인구독
소속 기관이 없으신 경우, 개인 정기구독을 하시면 저렴하게
논문을 무제한 열람 이용할 수 있어요.
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
Streptococcus pneumoniae (pneumococcus) is an important pathogen with high morbidity and mortality worldwide.
Pneumococcal vaccine is an important measure to reduce the pneumococcal disease burden. Currently, twopneumococcal vaccines are available in adults, including 23-valent pneumococcal polysaccharide vaccine (PPV23) and13-valent pneumococcal protein-conjugate vaccine (PCV13). PCV13 consists of capsular polysaccharides derived fromthe 13 most common types that cause invasive diseases (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, and 23F).
PPV23 covers 10 additional serotypes compared to PCV13, but it does not include serotype 6A. Even though limited in thenumber of serotypes, PCV13 has several important advantages over PPV23: T-cell dependent superior immunogenicity,booster effect, absence of hypo-responsiveness and protective effect on pneumonia. Although PPV23 is effective toprevent 50% to 80% of invasive pneumococcal diseases, it may be ineffective for high-risk immunocompetent andimmunocompromised patients. In adults, the choice of pneumococcal vaccine should be based on the severity ofunderlying medical conditions and local serotype distribution. Serotype distribution is quite variable temporally andgeographically. Continuous sero-surveillance is essential for the establishment of optimal vaccination strategy.
상세정보 수정요청해당 페이지 내 제목·저자·목차·페이지정보가 잘못된 경우 알려주세요!
목차
등록된 정보가 없습니다.